GlyCardial Diagnostics is honoured to announce the appointment of Dr. Andreas Calatzis as the non-executive Chairman of the Board of Directors.
Dr. Calatzis has more than 20 years’ experience in Research, Development and market introduction of in vitro diagnostic methods. Coinventor of 2 widely used IVD devices: ROTEM coagulation analyser for the management of acute bleeding in trauma, surgery and intensive care, acquired by Werfen in 2016; and Multiplate platelet function analyser for the optimization of anti-platelet therapy in cardiology and neurology, acquired by Roche in 2012. He worked 5 years for Roche Diagnostics (2012-2016). Currently CEO in the development of the ClotPro analyser.
Due to his extensive expertise in the development, manufacturing and marketing of IVD devices through managing positions he will be key in the strategic development of the company.